Jonathan Aschoff
Stock Analyst at Roth Capital
(0.49)
# 4,139
Out of 5,042 analysts
38
Total ratings
25%
Success rate
-35.72%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.68 | +1,507.01% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $10.61 | +97.93% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $1.52 | +389,373.68% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.57 | +1,046.50% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $3.25 | +21,869.23% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.57 | +3,430.45% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.49 | +8,130.45% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $4.00 | +20,900.00% | 4 | Mar 28, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $25 → $36 | $12.38 | +190.79% | 1 | Mar 7, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $6.70 | +268,556.72% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $7.39 | +305.95% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $8.34 | +2,298.08% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $3.61 | +287.81% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $1.27 | +1,700,687.40% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.61 | +396.89% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $4.88 | +1,949.18% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.10 | +36,263.64% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $10.75 | +253.49% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.33 | +4,020.17% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.90 | +584.21% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.68
Upside: +1,507.01%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $10.61
Upside: +97.93%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $1.52
Upside: +389,373.68%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.57
Upside: +1,046.50%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $3.25
Upside: +21,869.23%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.57
Upside: +3,430.45%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.49
Upside: +8,130.45%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $4.00
Upside: +20,900.00%
Mind Medicine (MindMed)
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $12.38
Upside: +190.79%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $6.70
Upside: +268,556.72%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $7.39
Upside: +305.95%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $8.34
Upside: +2,298.08%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $3.61
Upside: +287.81%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $1.27
Upside: +1,700,687.40%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.61
Upside: +396.89%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $4.88
Upside: +1,949.18%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $1.10
Upside: +36,263.64%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $10.75
Upside: +253.49%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.33
Upside: +4,020.17%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.90
Upside: +584.21%